英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
05320查看　05320　在百度字典中的解释百度英翻中〔查看〕
05320查看　05320　在Google字典中的解释Google英翻中〔查看〕
05320查看　05320　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Kurome Therapeutics, Inc. | LinkedIn
    Kurome Therapeutics, Inc | 463 abonnés sur LinkedIn A preclinical stage company focused on subverting cancer's ability to evade therapy | Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms
  • Kurome Therapeutics, Inc. | LinkedIn
    Kurome Therapeutics, Inc | 741 followers on LinkedIn A preclinical stage company focused on subverting cancer #39;s ability to evade therapy | Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms Kurome Therapeutics is a
  • Kurome Therapeutics, Inc. | LinkedIn
    Kurome Therapeutics, Inc | 822 followers on LinkedIn A preclinical stage company focused on subverting cancer #39;s ability to evade therapy | Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms Kurome Therapeutics is a
  • Kurome Therapeutics, Inc. | LinkedIn
    Kurome Therapeutics, Inc | 780 followers on LinkedIn A preclinical stage company focused on subverting cancer #39;s ability to evade therapy | Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms Kurome Therapeutics is a
  • Kurome Therapeutics, Inc. | LinkedIn
    Kurome Therapeutics, Inc | 407 followers on LinkedIn A preclinical stage company focused on subverting cancer #39;s ability to evade therapy | Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms Kurome Therapeutics is a
  • Kurome Therapeutics, Inc. | LinkedIn
    Kurome Therapeutics, Inc | 627 followers on LinkedIn A preclinical stage company focused on subverting cancer #39;s ability to evade therapy | Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms Kurome Therapeutics is a
  • Kurome Therapeutics, Inc. | LinkedIn
    Kurome Therapeutics, Inc | 584 followers on LinkedIn A preclinical stage company focused on subverting cancer #39;s ability to evade therapy | Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms Kurome Therapeutics is a
  • Kurome Therapeutics, Inc. | LinkedIn
    Kurome Therapeutics, Inc | 696 followers on LinkedIn A preclinical stage company focused on subverting cancer #39;s ability to evade therapy | Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms Kurome Therapeutics is a
  • Kurome Therapeutics, Inc. | LinkedIn
    Kurome Therapeutics, Inc | 586 seguidores no LinkedIn A preclinical stage company focused on subverting cancer's ability to evade therapy | Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms
  • Kurome Therapeutics, Inc. | LinkedIn
    Kurome Therapeutics, Inc | 464 followers on LinkedIn A preclinical stage company focused on subverting cancer #39;s ability to evade therapy | Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms Kurome Therapeutics is a
  • Top Targeted chemotherapy drugs start-ups - VentureRadar
    Kurome Therapeutics Private Company Founded 2019 USA Kuromeis developing combined IRAK1 4 and panFLT3 inhibitors to target cancer cells that evade the effects of chemotherapy drugs by adaptive resistance, having co-opted immune signaling pathways to survive
  • Kurome Therapeutics, Inc. | LinkedIn
    Kurome Therapeutics, Inc | 738 seguidores no LinkedIn A preclinical stage company focused on subverting cancer's ability to evade therapy | Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms
  • Kurome Therapeutics, Inc. | LinkedIn
    Kurome Therapeutics, Inc | 717 followers on LinkedIn A preclinical stage company focused on subverting cancer #39;s ability to evade therapy | Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms Kurome Therapeutics is a
  • Kurome Therapeutics, Inc. | LinkedIn
    Kurome Therapeutics, Inc | 583 followers on LinkedIn A preclinical stage company focused on subverting cancer #39;s ability to evade therapy | Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms Kurome Therapeutics is a
  • Kurome Therapeutics, Inc. | LinkedIn
    Kurome Therapeutics, Inc | 647 seguidores en LinkedIn A preclinical stage company focused on subverting cancer's ability to evade therapy | Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms





中文字典-英文字典  2005-2009